Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Companies / PharmAla Biotech Holdings
Company

PharmAla Biotech Holdings

Tracked across 2 events · 13 articles · First seen Jul 06, 2026 · Last active Jul 21, 2026

Sentiment
62
Attention
4
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (2)
4 75
Business
PharmAla ALA-002 Manufacturing, Patent, Australia
Impact: PharmAla Biotech Holdings successfully completed GMP manufacturing of drug substance for Non-racemic MDMA, was granted an Australian patent for Non-racemic MDMA, and will brand Non-racemic MDMA as LaNeo Gen 2 in Australia. These advancements position the company for upcoming clinical activities and commercialization.
Jul 06, 2026 · 7 articles
2 50
Business
Jupiter licenses ALA-002 from PharmAla
Impact: PharmAla is the licensor, receiving upfront payment and milestone payments, and will continue manufacturing ALA-002 for Jupiter.
Jul 21, 2026 · 6 articles
ERGEN INTELLIGENCE
Track PharmAla Biotech Holdings live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.